SCHEMBL17454013

SCHEMBL17454013

CCCCOc1ccc2c(C(=O)OC)cnn2c1C#N

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.39
▸ HPGD P15428 2/20 0.39
▸ KDM4E B2RXH2 2/20 0.39
▸ TP53 P04637 2/20 0.39
▸ GAA P10253 2/20 0.39
▸ TSHR P16473 2/20 0.39
▸ GLA P06280 1/20 0.39
▸ ALOX15 P16050 1/20 0.39
▸ CRHBP P24387 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ CASP1 P29466 1/20 0.39
▸ CASP7 P55210 1/20 0.39
▸ ATM Q13315 1/20 0.39
▸ CRHR2 Q13324 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ HTT P42858 1/20 0.37
▸ PLA2G4A P47712 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17454011 0.83 TSHR (0.41) ALDH1A1HPGDKDM4ETP53GAA
SCHEMBL17454373 0.83 TP53 (0.42) ALDH1A1HPGDKDM4ETP53GAA
SCHEMBL17454014 0.82 TP53 (0.41) ALDH1A1HPGDKDM4ETP53GAA
SCHEMBL17455480 0.82 KDM4E (0.41) ALDH1A1HPGDKDM4ETP53GAA
SCHEMBL19150023 0.80 TP53 (0.39) ALDH1A1HPGDKDM4ETP53GAA
SCHEMBL17454445 0.79 TP53 (0.38) ALDH1A1HPGDKDM4ETP53GAA
SCHEMBL17454441 0.79 SPR (0.43) ALDH1A1HPGDKDM4ETP53GAA
SCHEMBL17437878 0.78 KDM4E (0.40) ALDH1A1HPGDKDM4ETP53GAA
SCHEMBL19150259 0.76 ALDH1A1 (0.36) ALDH1A1HPGDKDM4ETP53GAA
SCHEMBL31528324 0.69 TLR8 (0.40) ALDH1A1HPGDKDM4ETP53GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160016914-A1 SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK BRISTOL-MYERS SQUIBB COMPANY 2016-01-21 — — US disclosed
WO-2016010950-A1 SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK BRISTOL-MYERS SQUIBB COMPANY (US) 2016-01-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160016914-A1 SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK ROCK1, MYLK, ROCK2 ALDH1A1 1252/4885HPGD 749/4885KDM4E 1546/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback